Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Phase 1 Terminated
12 enrolled
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Phase 1 Terminated
40 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1 Terminated
6 enrolled 11 charts
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1 Terminated
37 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 1 Terminated
8 enrolled
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Phase 1 Terminated
212 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Phase 1 Terminated
4 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
Phase 1 Terminated
19 enrolled
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
Phase 1 Terminated
96 enrolled
AM-003
Phase 1 Terminated
5 enrolled
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
9 enrolled
Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
Phase 1 Terminated
25 enrolled
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
Phase 1 Terminated
2 enrolled 5 charts
ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer
Phase 1 Terminated
9 enrolled 14 charts
A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
Phase 1 Terminated
54 enrolled
EUCLIDIAN
Phase 1 Terminated
2 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
Phase 1 Terminated
47 enrolled
EPI-7386
Phase 1 Terminated
71 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Phase 1 Terminated
40 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
A Study of SGN-ALPV in Advanced Solid Tumors
Phase 1 Terminated
43 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
Phase 1 Terminated
19 enrolled
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
LTbR
Phase 1 Terminated
4 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
CAR
Phase 1 Terminated
9 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
PK and Dose Escalation and Expansion Study of DST-2970
Phase 1 Terminated
26 enrolled
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
Phase 1 Terminated
6 enrolled
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Phase 1 Terminated
60 enrolled
Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer
Phase 1 Terminated
13 enrolled
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
Phase 1 Terminated
14 enrolled
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC
Phase 1 Terminated
11 enrolled
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Phase 1 Terminated
3 enrolled
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Phase 1 Terminated
3 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts